MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.2012.48.3990

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013

Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.

Link Brian K, Maurer Matthew J, Nowakowski Grzegorz S, Ansell Stephen M, Macon William R, Syrbu Sergei I, Slager Susan L, Thompson Carrie A, Inwards David J, Johnston Patrick B, Colgan Joseph P, Witzig Thomas E, Habermann Thomas M, Cerhan James R

СтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

PURPOSE: This study sought to characterize transformation incidence and outcome for patients with follicular lymphoma (FL) in a prospective observational series begun after diffusion of rituximab use.

PATIENTS AND

METHODS

Patients with newly diagnosed FL were prospectively enrolled onto the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource from 2002 to 2009. Patients were actively followed for re-treatment, clinical or pathologic transformation, and death. Risk of transformation was analyzed via time to transformation by using death as a competing risk.

RESULTS

In all, there were 631 patients with newly diagnosed grade 1 to 3a FL who had a median age at enrollment of 60 years. At a median follow-up of 60 months (range, 11 to 110 months), 79 patients had died, and 60 patients developed transformed lymphoma, of which 51 were biopsy proven. The overall transformation rate at 5 years was 10.7%, with an estimated rate of 2% per year. Increased lactate dehydrogenase was associated with increased risk of transformation. Transformation rate at 5 years was highest in patients who were initially observed and lowest in patients who initially received rituximab monotherapy (14.4% v 3.2%; P = .021). Median overall survival following transformation was 50 months and was superior in patients with transformation greater than 18 months after FL diagnosis compared with patients with earlier transformation (5-year overall survival, 66% v 22%; P < .001).

CONCLUSION

Follicular transformation rates in the immunochemotherapy era are similar to risk of death without transformation and may be lower than reported in older series. Post-transformation prognosis is substantially better than described in older series. Initial management strategies may influence the risk of transformation.

Для цитирования: Link Brian K, Maurer Matthew J, Nowakowski Grzegorz S, Ansell Stephen M, Macon William R, Syrbu Sergei I, Slager Susan L, Thompson Carrie A, Inwards David J, Johnston Patrick B, Colgan Joseph P, Witzig Thomas E, Habermann Thomas M, Cerhan James R. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013. DOI: 10.1200/jco.2012.48.3990.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.